David Zhang is the co-founder/CEO of Biostate AI, a venture-backed startup building individualized health AI to predict disease evolution and drug response based on RNA expression data.  Before Biostate AI, David was co-founder/CEO of NuProbe, a startup that raised over $110M of venture capital to build affordable non-invasive cancer minimum residual disease tests.  Before NuProbe, David was a tenured professor of Bioengineering at Rice University, where his group published over 30 peer-reviewed articles.